FORA Capital’s ADC Therapeutics ADCT Stock Holding History

FORA Capital’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,089	Closed	-$27K	–	342
2021 Q2	$27K	Buy	+1,089	New	+$25.3K	0.01%	796

Other funds holding ADCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

FORA Capital's ADCT Position: Q3 2021 in Review

FORA Capital sold out of ADC Therapeutics (ADCT) in Q3 2021, closing a stake of 1,089 shares — an estimated $27K sold.

FORA Capital first reported a position in ADCT in Q2 2021 and held it in 1 quarter. The position peaked at $27K in Q2 2021. 53 funds tracked by Wall St. Rank hold ADCT as of Q3 2021.

FORA Capital reported no remaining ADC Therapeutics position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 1,089 ADC Therapeutics shares in Q3 2021, an estimated $27K.
FORA Capital first reported a position in ADC Therapeutics in Q2 2021 and held it in 1 quarter.
FORA Capital's ADC Therapeutics position peaked at $27K in Q2 2021.
53 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.